Judgment — ECLI:EU:C:2024:553
Date: 2024-06-27
Language of the case: French
Court formation: First Chamber
Subject matter: Competition;Agreements, decisions and concerted practices
Procedure: Action for annulment;Appeal - unfounded
Origin: France

Judgment of the Court (First Chamber) of 27 June 2024 – Biogaran SAS v European Commission (Case C-207/19 P) 1 (Appeal – Competition – Pharmaceutical products – Market for perindopril – Article 101 TFEU – Strategy to delay the market entry of generic versions of perindopril – Patent dispute settlement agreement – Licence and supply agreement) Language of the case: French Parties Appellant: Biogaran SAS (represented by: O. de Juvigny, J. Jourdan, T. Reymond, A. Robert, avocats, J. Killick, advocaat, and M.I.F. Utges Manley, Solicitor) Other party to the proceedings: European Commission (represented initially by F. Castilla Contreras, B. Mongin, and C. Vollrath, acting as Agents, and subsequently by F. Castilla Contreras and C. Vollrath, acting as Agents) Intervener in support of the other party: United Kingdom of Great Britain and Northern Ireland (represented initially by D. Guðmundsdóttir, acting as Agent, and subsequently by S. Fuller, acting as Agent) Operative part of the judgment The Court: Dismisses the appeal; Orders Biogaran SAS to bear its own costs and to pay those incurred by the European Commission; Orders the United Kingdom of Great Britain and Northern Ireland to bear its own costs. ____________ 1 OJ C 139, 15.4.2019.